
Opinion|Videos|May 23, 2024
Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause
Author(s)Anjali Tiku Owens, MD
Anjali Tiku Owens, MD, examines the unmet needs in treating obstructive hypertrophic cardiomyopathy (oHCM) and explores how novel Cardiac Myosin inhibitors (CMIs) address the root cause of the condition.
Advertisement
Episodes in this series

Now Playing
- The treatment of obstructive hypertrophic cardiomyopathy (oHCM) has a high level of unmet needs, can you discuss these with us?
- How do novel cardiac myosin inhibitors (CMIs) target the underlying cause of oHCM?
2. What has the impact of CMI’s been on the management of oHCM?
- Complements (first line) standard of care
- Addresses the root cause of oHCM
- Narrowing the substantial gap between effective medical therapy and the more definitive invasive treatments like alcohol septal ablation and surgical myectomy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Libre Duo 10 Day Authorized as First Glucose-Ketone Monitor for Diabetes
2
Psoriasis Awareness & Action Month: New Oral Drugs and Other Developments
3
FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
4
TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD
5








































































